AG
SYRE icon

Artal Group’s Spyre Therapeutics SYRE Stock Holding History

Artal Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-41,800
Closed -$4.96M – 147
2021
Q4 		$4.96M Hold
41,800
– – 0.13% 103
2021
Q3 		$8.31M Hold
41,800
– – 0.19% 91
2021
Q2 		$7.27M Hold
41,800
– – 0.15% 109
2021
Q1 		$8.28M Hold
41,800
– – 0.15% 106
2020
Q4 		$8.22M Hold
41,800
– – 0.18% 93
2020
Q3 		$7.41M Sell
41,800
-2,200
-5% -$407K 0.18% 85
2020
Q2 		$10.2M Buy
44,000
+28,000
+175% +$5.33M 0.28% 68
2020
Q1 		$1.86M Buy
16,000
+4,000
+33% +$680K 0.08% 98
2019
Q4 		$2.29M Hold
12,000
– – 0.09% 92
2019
Q3 		$2.31M Buy
12,000
+5,242
+78% +$1.02M 0.09% 95
2019
Q2 		$1.16M Buy
+6,758
New +$1.17M 0.05% 100

Other funds holding SYRE

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Artal Group's SYRE Position: Q1 2022 in Review

Artal Group sold out of Spyre Therapeutics (SYRE) in Q1 2022, closing a stake of 41,800 shares — an estimated $4.96M sold.

Artal Group first reported a position in SYRE in Q2 2019 and held it in 11 quarters. The position peaked at $10.2M in Q2 2020. 83 funds tracked by Wall St. Rank hold SYRE as of Q1 2022.

  • Artal Group reported no remaining Spyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Artal Group sold 41,800 Spyre Therapeutics shares in Q1 2022, an estimated $4.96M.
  • Artal Group first reported a position in Spyre Therapeutics in Q2 2019 and held it in 11 quarters.
  • Artal Group's Spyre Therapeutics position peaked at $10.2M in Q2 2020.
  • 83 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2022.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.